400-920-2911 sales@csnpharm.cn
您的位置 : 首页 / PI3K/Akt/mTOR / PI3K / Alpelisib/阿培利司
CAS No.: 1217486-61-7
Synonyms: BYL-719;NVP-BYL719
Alpelisib is a potent and selective PI3Kα inhibitor with IC50 of 5 nM, liitle or no effect on PI3Kβ/γ/δ.
生物活性
靶点 | PI3Kα IC50:5nM |
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
---|---|---|---|---|---|
NCT02167854 | Breast Cancer | Phase 1 | Active, not recruiting | June 2019 | United States, New Jersey ... more >> Memorial Sloan Kettering at Basking Ridge Basking Ridge, New Jersey, United States, 07920 Memorial Sloan Kettering Monmouth Middletown, New Jersey, United States, 07748 United States, New York Memorial Sloan Kettering Commack Commack, New York, United States, 11725 Memoral Sloan Kettering Westchester Harrison, New York, United States, 10604 Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 Memorial Sloan Kettering Rockville Centre Rockville Centre, New York, United States, 11570 Collapse << |
NCT02734615 | Advanced or Metastatic ER+ Bre... more >>ast Cancer Collapse << | Phase 1 | Recruiting | October 30, 2020 | United States, Maryland ... more >> Novartis Investigative Site Recruiting Baltimore, Maryland, United States, 21287 United States, Massachusetts Massachusetts General Hospital Massachusetts General Hospital Recruiting Boston, Massachusetts, United States, 02114 Contact: Dejan Juric, MD 617-726-6500 Juric.Dejan@mgh.harvard.edu Contact: Meghan Miles 617-726-6500 MEMILES@mgh.harvard.edu Principal Investigator: Dejan Juric, MD United States, New York Novartis Investigative Site Recruiting New York, New York, United States, 10021 Contact: Alexandra Burleigh 646-422-4394 burleiga@mskcc.org Principal Investigator: Komal Jhaveri United States, Texas Novartis Investigative Site Recruiting Houston, Texas, United States, 77030 Contact: Daniela Westerhold diwesterhold@mdanderson.org Principal Investigator: Rachel M Layman Belgium Novartis Investigative Site Recruiting Bruxelles, Belgium, 1200 Canada, Ontario Novartis Investigative Site Recruiting Toronto, Ontario, Canada, M5G 2M9 France Novartis Investigative Site Recruiting Lyon Cedex, France, 69373 Italy Novartis Investigative Site Recruiting Milano, MI, Italy, 20133 Novartis Investigative Site Recruiting Milano, MI, Italy, 20141 Japan Novartis Investigative Site Recruiting Koto-ku, Tokyo, Japan, 135 8550 Singapore Novartis Investigative Site Recruiting Singapore, Singapore, 169610 Spain Novartis Investigative Site Recruiting Barcelona, Catalunya, Spain, 08036 Novartis Investigative Site Recruiting Madrid, Spain, 28007 Collapse << |
NCT03138070 | Head and Neck Squamous Cell Ca... more >>ncer Collapse << | Not Applicable | Recruiting | May 2020 | Canada, Ontario ... more >> London Health Sciences Centre, London Regional Cancer Program Recruiting London, Ontario, Canada, N6A 4L6 Contact: Anthony Nichols 519-685-8500 ext 58804 anthony.nichols@lhsc.on.ca Contact: Shamim Mortuza 519-685-8500 ext 58618 shamim.mortuza@lhsc.on.ca Collapse << |
实验方案
技术信息
CAS号 | 1217486-61-7 | 储存条件 |
|
|||||||||||||
分子式 | C19H22F3N5O2S | 运输 | 蓝冰 | |||||||||||||
分子量 | 441.47 | 别名 | BYL-719;NVP-BYL719 | |||||||||||||
溶解度 |
|
动物实验配方 |
|
Cell Lines | Concentration | Assay Type | Time | Activity Description | Data Sources |
---|
92.1 | 500-2000 nM | Growth Inhibition Assay | 5 d | inhibits the phosphorylation of AKT (Ser473) up to 1 μM | 24563540 |
AU565 | 33 μM | Growth Inhibition Assay | 5 d | inhibits 26% cell growth | 23918797 |
BON-1 | 1/10 μM | Function Assay | 4 h | inhibits PI3K (AKT Ser308) and mTORC1/2 activities | 25026292 |
BT474 | 33 μM | Growth Inhibition Assay | 5 d | inhibits 16% cell growth | 23918797 |
C918 | 500-2000 nM | Growth Inhibition Assay | 5 d | inhibits the phosphorylation of AKT (Ser473) up to 1 μM | 24563540 |
Detroit562 | 0.1-100 μM | Growth Inhibition Assay | 72 h | IC50=1.10 μM | 25550549 |
EFM192A | 33 μM | Growth Inhibition Assay | 5 d | inhibits 27% cell growth | 23918797 |
FaDu | 0.1-100 μM | Growth Inhibition Assay | 72 h | IC50=19.66 μM | 25550549 |
H929 | 0.5-2.5 μM | Growth Inhibition Assay | 48 h | inhibits cell growth in a dose-dependent manner | 24405121 |
HCC1569 | 33 μM | Growth Inhibition Assay | 5 d | inhibits 5% cell growth | 23918797 |
HCC1954 | 33 μM | Growth Inhibition Assay | 5 d | inhibits 29% cell growth | 23918797 |
HCC202 | 33 μM | Growth Inhibition Assay | 5 d | inhibits 20% cell growth | 23918797 |
HCC2218 | 33 μM | Growth Inhibition Assay | 5 d | inhibits 15% cell growth | 23918797 |
HOS | - | Growth Inhibition Assay | - | IC50=15 μM, IC90=42 μM | 24961790 |
JIMT1 | 33 μM | Growth Inhibition Assay | 5 d | inhibits 9% cell growth | 23918797 |
KPL4 | 33 μM | Growth Inhibition Assay | 5 d | inhibits 58% cell growth | 23918797 |
MDA361 | 33 μM | Growth Inhibition Assay | 5 d | inhibits 44% cell growth | 23918797 |
MDA453 | 33 μM | Growth Inhibition Assay | 5 d | inhibits 38% cell growth | 23918797 |
Mel270 | 500-2000 nM | Growth Inhibition Assay | 5 d | inhibits the phosphorylation of AKT (Ser473) up to 1 μM | 24563540 |
Mel290 | 500-2000 nM | Growth Inhibition Assay | 5 d | inhibits the phosphorylation of AKT (Ser473) up to 1 μM | 24563540 |
MG-63 | - | Growth Inhibition Assay | - | IC50=6 μM, IC90=24 μM | 24961790 |
MM1R | 0.5-2.5 μM | Growth Inhibition Assay | 48 h | inhibits cell growth in a dose-dependent manner | 24405121 |
MM1S | 0.5-2.5 μM | Growth Inhibition Assay | 48 h | inhibits cell growth in a dose-dependent manner | 24405121 |
MOS-J | - | Growth Inhibition Assay | - | IC50=10 μM, IC90=36 μM | 24961790 |
NCL-N87 | 33 μM | Growth Inhibition Assay | 5 d | inhibits 31% cell growth | 23918797 |
NUGC4 | 33 μM | Growth Inhibition Assay | 5 d | inhibits 14% cell growth | 23918797 |
OE19 | 33 μM | Growth Inhibition Assay | 5 d | inhibits 23% cell growth | 23918797 |
OE33 | 33 μM | Growth Inhibition Assay | 5 d | inhibits 23% cell growth | 23918797 |
Omm1 | 500-2000 nM | Growth Inhibition Assay | 5 d | inhibits the phosphorylation of AKT (Ser473) up to 1 μM | 24563540 |
Omm1.3 | 500-2000 nM | Growth Inhibition Assay | 5 d | inhibits the phosphorylation of AKT (Ser473) up to 1 μM | 24563540 |
OPM1 | 0.5-2.5 μM | Growth Inhibition Assay | 48 h | inhibits cell growth in a dose-dependent manner | 24405121 |
OPM2 | 0.5-2.5 μM | Growth Inhibition Assay | 48 h | inhibits cell growth in a dose-dependent manner | 24405121 |
POS-1 | - | Growth Inhibition Assay | - | IC50=8 μM, IC90=36 μM | 24961790 |
QGP-1 | 1/10 μM | Function Assay | 4 h | inhibits PI3K (AKT Ser308) and mTORC1/2 activities | 25026292 |
RPMI | 0.5-2.5 μM | Growth Inhibition Assay | 48 h | inhibits cell growth in a dose-dependent manner | 24405121 |
SCC25 | 0.1-100 μM | Growth Inhibition Assay | 72 h | IC50=49.30 μM | 25550549 |
SKBR3 | 33 μM | Growth Inhibition Assay | 5 d | inhibits 35% cell growth | 23918797 |
SNU1041 | 0.1-100 μM | Growth Inhibition Assay | 72 h | IC50=20.65 μM | 25550549 |
SNU-1066 | 0.1-100 μM | Growth Inhibition Assay | 72 h | IC50=1.13 μM | 25550549 |
SNU-1076 | 0.1-100 μM | Growth Inhibition Assay | 72 h | IC50=6.82 μM | 25550549 |
U266 | 0.5-2.5 μM | Growth Inhibition Assay | 48 h | inhibits cell growth in a dose-dependent manner | 24405121 |
UACC812 | 33 μM | Growth Inhibition Assay | 5 d | inhibits 27% cell growth | 23918797 |
ZR-75-30 | 33 μM | Growth Inhibition Assay | 5 d | inhibits -15% cell growth | 23918797 |
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
---|
NCT02167854 | Breast Cancer | Phase 1 | Active, not recruiting | June 2019 | United States, New Jersey ... more >> Memorial Sloan Kettering at Basking Ridge Basking Ridge, New Jersey, United States, 07920 Memorial Sloan Kettering Monmouth Middletown, New Jersey, United States, 07748 United States, New York Memorial Sloan Kettering Commack Commack, New York, United States, 11725 Memoral Sloan Kettering Westchester Harrison, New York, United States, 10604 Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 Memorial Sloan Kettering Rockville Centre Rockville Centre, New York, United States, 11570 Collapse << |
NCT02734615 | Advanced or Metastatic ER+ Bre... more >>ast Cancer Collapse << | Phase 1 | Recruiting | October 30, 2020 | United States, Maryland ... more >> Novartis Investigative Site Recruiting Baltimore, Maryland, United States, 21287 United States, Massachusetts Massachusetts General Hospital Massachusetts General Hospital Recruiting Boston, Massachusetts, United States, 02114 Contact: Dejan Juric, MD 617-726-6500 Juric.Dejan@mgh.harvard.edu Contact: Meghan Miles 617-726-6500 MEMILES@mgh.harvard.edu Principal Investigator: Dejan Juric, MD United States, New York Novartis Investigative Site Recruiting New York, New York, United States, 10021 Contact: Alexandra Burleigh 646-422-4394 burleiga@mskcc.org Principal Investigator: Komal Jhaveri United States, Texas Novartis Investigative Site Recruiting Houston, Texas, United States, 77030 Contact: Daniela Westerhold diwesterhold@mdanderson.org Principal Investigator: Rachel M Layman Belgium Novartis Investigative Site Recruiting Bruxelles, Belgium, 1200 Canada, Ontario Novartis Investigative Site Recruiting Toronto, Ontario, Canada, M5G 2M9 France Novartis Investigative Site Recruiting Lyon Cedex, France, 69373 Italy Novartis Investigative Site Recruiting Milano, MI, Italy, 20133 Novartis Investigative Site Recruiting Milano, MI, Italy, 20141 Japan Novartis Investigative Site Recruiting Koto-ku, Tokyo, Japan, 135 8550 Singapore Novartis Investigative Site Recruiting Singapore, Singapore, 169610 Spain Novartis Investigative Site Recruiting Barcelona, Catalunya, Spain, 08036 Novartis Investigative Site Recruiting Madrid, Spain, 28007 Collapse << |
NCT03138070 | Head and Neck Squamous Cell Ca... more >>ncer Collapse << | Not Applicable | Recruiting | May 2020 | Canada, Ontario ... more >> London Health Sciences Centre, London Regional Cancer Program Recruiting London, Ontario, Canada, N6A 4L6 Contact: Anthony Nichols 519-685-8500 ext 58804 anthony.nichols@lhsc.on.ca Contact: Shamim Mortuza 519-685-8500 ext 58618 shamim.mortuza@lhsc.on.ca Collapse << |
NCT01602315 | Recurrent Head and Neck Squamo... more >>us Cell Carcinoma Metastatic Head and Neck Squamous Cell Carcinoma Collapse << | Phase 1 Phase 2 | Terminated(early termination d... more >>ue to Sponsor decision (slow recruitment)) Collapse << | - | - |
NCT01708161 | PIK3CA Mutated Advanced Solid ... more >>Tumors PIK3CA Amplified Advanced Solid Tumors Collapse << | Phase 1 Phase 2 | Terminated | - | United States, California ... more >> Novartis Investigative Site Los Angeles, California, United States, 90095 United States, Massachusetts Novartis Investigative Site Boston, Massachusetts, United States, 02114 United States, New York Novartis Investigative Site New York, New York, United States, 10017 United States, Tennessee Novartis Investigative Site Nashville, Tennessee, United States, 37203 Belgium Novartis Investigative Site Leuven, Belgium, 3000 Canada, Ontario Novartis Investigative Site Toronto, Ontario, Canada, M5G 1Z6 Spain Novartis Investigative Site Sevilla, Andalucia, Spain, 41013 Novartis Investigative Site Barcelona, Catalunya, Spain, 08035 Novartis Investigative Site Madrid, Spain, 28033 Novartis Investigative Site Madrid, Spain, 28041 Collapse << |
NCT01923168 | Breast Cancer | Phase 2 | Completed | - | - |
NCT01923168 | - | - | Completed | - | - |
NCT01602315 | - | - | Terminated(early termination d... more >>ue to Sponsor decision (slow recruitment)) Collapse << | - | - |
NCT03706573 | - | - | - | - | - |
NCT01708161 | - | - | Terminated | - | - |
NCT03056755 | Breast Cancer | Phase 2 | Recruiting | April 10, 2020 | - |
NCT03601507 | CDKN2A-p16 Positive ... more >> Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma Stage I Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7 Stage II Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7 Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7 Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7 Collapse << | Phase 2 | Recruiting | December 31, 2022 | United States, Arizona ... more >> The University of Arizona Medical Center-University Campus Recruiting Tucson, Arizona, United States, 85724 Contact: Julie E. Bauman 520-626-4101 jebauman@email.arizona.edu Principal Investigator: Julie E. Bauman Collapse << |
NCT02624557 | Hepatic Impairment | Phase 1 | Completed | - | United States, Colorado ... more >> DaVita Clinical Research-Denver Lakewood, Colorado, United States, 80228 United States, Florida University of Miami / Clinical Research Services, Inc. Miami, Florida, United States, 33136 Orlando Clinical Research Center Orlando, Florida, United States, 32809 United States, Minnesota DaVita Clinical Research Minneapolis, Minnesota, United States, 55404 Collapse << |
NCT02058381 | Pre-menopausal Breast Cancer ... more >> PI3K Pathway Inhibition Collapse << | Phase 1 | Completed | - | Hong Kong ... more >> Novartis Investigative Site Hong Kong, Hong Kong Korea, Republic of Novartis Investigative Site Seongnam-si, Gyeonggi-do, Korea, Republic of, 13620 Novartis Investigative Site Gyeonggi-do, Korea, Korea, Republic of, 10408 Novartis Investigative Site Seoul, Korea, Korea, Republic of, 05505 Novartis Investigative Site Seoul, Korea, Korea, Republic of, 06351 Novartis Investigative Site Seoul, Korea, Republic of, 03722 Taiwan Novartis Investigative Site Kuei-Shan Chiang, Taoyuan/ Taiwan ROC, Taiwan, 33305 Novartis Investigative Site New Taipei City, TWN, Taiwan, 23561 Novartis Investigative Site Kaohsiung City, Taiwan, 83301 Novartis Investigative Site Taichung, Taiwan, 407 Novartis Investigative Site Taipei, Taiwan, 10002 Novartis Investigative Site Taipei, Taiwan, 10449 Novartis Investigative Site Taipei, Taiwan, 112 Thailand Novartis Investigative Site Bangkok, Thailand, 10330 Novartis Investigative Site Chiang Mai, Thailand, 50200 Collapse << |
NCT02437318 | Breast Cancer | Phase 3 | Active, not recruiting | April 15, 2020 | - |
NCT03631953 | Meningioma | Phase 1 | Not yet recruiting | January 1, 2022 | France ... more >> Assistance Publique Hôpitaux de Marseille Not yet recruiting Marseille, France, 13354 Contact: Thomas GRAILLON, PH 491385545 ext +33 thomas.graillon@ap-hm.fr Contact: Olivier CHINOT, PU-PH 491385545 ext +33 olivier.chinot@ap-hm.fr Principal Investigator: Thomas GRAILLON, PH Collapse << |
NCT03207529 | Malignant Neoplasm of Breast | Phase 1 | Not yet recruiting | January 2021 | United States, Texas ... more >> University of Texas MD Anderson Cancer Center Not yet recruiting Houston, Texas, United States, 77030 Contact: Clinical Research Operations mskaruturi@mdanderson.org Collapse << |
NCT02077933 | Neoplasms Bre... more >>ast Neoplasms Kidney Neoplasms Pancreatic Neuroendocine Neoplasms Collapse << | Phase 1 | Active, not recruiting | November 30, 2018 | United States, Arkansas ... more >> Highlands Oncology Group Fayetteville, Arkansas, United States, 72703 United States, New York Memorial Sloan Kettering Cancer Center SC - BYL719Z2102 New York, New York, United States, 10065 France Novartis Investigative Site Bordeaux Cedex, France, 33075 Novartis Investigative Site Bordeaux, France, 33076 Novartis Investigative Site Villejuif Cedex, France, 94805 Germany Novartis Investigative Site Berlin, Germany, 12203 Novartis Investigative Site Essen, Germany, 45136 Novartis Investigative Site Essen, Germany, 45147 Novartis Investigative Site Hannover, Germany, 30625 Hong Kong Novartis Investigative Site Hong Kong, Hong Kong Hungary Novartis Investigative Site Budapest, Hungary, H-1077 Italy Novartis Investigative Site Ancona, AN, Italy, 60126 Novartis Investigative Site Milano, MI, Italy, 20141 Novartis Investigative Site Modena, MO, Italy, 41124 Novartis Investigative Site Verona, VR, Italy, 37126 Netherlands Novartis Investigative Site Amsterdam, Netherlands, 1066 CX Novartis Investigative Site Utrecht, Netherlands, 3584CX Spain Novartis Investigative Site Barcelona, Catalunya, Spain, 08036 Novartis Investigative Site Madrid, Spain, 28007 Novartis Investigative Site Madrid, Spain, 28034 United Kingdom Novartis Investigative Site Manchester, United Kingdom, M20 4BX Collapse << |
NCT03386162 | Breast Cancer, PI3K, Alpelisib | Phase 2 | Recruiting | July 1, 2023 | France ... more >> Institut de Cancérologie de l'Ouest/Paul Papin Recruiting Angers, France Contact: Mario CAMPONE, MD, PhD mario.campone@ico.unicancer.fr Principal Investigator: Mario CAMPONE, MD, PhD Institut Sainte-Catherine Recruiting Avignon, France Contact: Alice Mege, MD Principal Investigator: Alice Mege, MD Institut Bergonié Recruiting Bordeaux, France Contact: Marc DEBLED, MD Principal Investigator: Marc DEBLED, MD Polyclinique Bordeaux Nord Aquitaine Recruiting Bordeaux, France Contact: Nadine DOHOLLOU, MD Centre François Baclesse Recruiting Caen, France Contact: Christelle Levy Principal Investigator: Christelle Levy, MD Centre Jean Perrin Recruiting Clermont-ferrand, France, 63011 Contact: Marie-Ange MOURET-REYNIER Principal Investigator: Marie Ange MOURET-REYNIER CH Alpes Leman Recruiting Contamine-sur-Arve, France Contact: Carol ALLIOT, MD Centre de Lutte Contre le Cancer Georges-Francois Leclerc Recruiting Dijon, France, 21079 Contact: Nicolas Isambert, MD 33-3-8073-7506 Chd Vendee Recruiting La Roche Sur Yon, France Contact: Tifenn L'HARIDON, MD Principal Investigator: Tifenn L'HARIDON, MD Centre Oscar Lambret Recruiting Lille, France Contact: Nuria KOTECKI, MD Principal Investigator: Nuria KOTECKI, MD CHU Dupuytren Recruiting Limoges, France Contact: Laurence VENAT-BOUVET, MD Centre Hospitalier Lyon Sud Recruiting Lyon, France Contact: Benoit You, MD Principal Investigator: Benoit You, MD Centre Leon Berard Recruiting Lyon, France Contact: Thomas BACHELOT, MD Principal Investigator: Thomas BACHELOT, MD Hôpital Privé Jean Mermoz Recruiting Lyon, France Contact: Olfa DERBEL, MD Institut Paoli Calmettes Recruiting Marseille, France Contact: Anthony Gonçalves, MD, PhD Principal Investigator: Anthony Gonçalves, MD, PhD CInstitut Regional du cancer-Centre Val D'Aurelle Recruiting Montpellier, France Contact: William JACOT, MD Principal Investigator: William JACOT, MD Centre Alexis Vautrin Recruiting Nancy, France Contact: Vicent Massard Principal Investigator: Vincent Massard, MD Institut de Cancérologie de l'Ouest/ René Gauducheau Recruiting Nantes, France Contact: Mario Campone, MD, PhD Principal Investigator: Mario Campone, MD, PhD Centre Antoine Lacassagne Recruiting Nice, France Contact: Jean-Marc Ferrero Principal Investigator: Jean-Marc Ferrero, MD Institut Curie Recruiting Paris, France Contact: Marie-Paule Sablin, MD mariepaule.sablin@curie.fr Principal Investigator: Marie-Paule Sablin, MD Centre Eugène Marquis Recruiting Rennes, France Contact: Claudia Lefeuvre Plesse Principal Investigator: Claudia Lefeuvre Plesse, MD Centre Henri Becquerel Recruiting Rouen, France Contact: Jean-Christophe Théry, MD Principal Investigator: Jean-Christophe Théry, MD Centre Rene Huguenin Recruiting Saint Cloud, France, 92211 Contact: Florence COUSSY, MD Chru Strasbourg - Nouvel Hopital Civil Recruiting Strasbourg, France Contact: Philippe BARTHELEMY, MD Principal Investigator: Philippe BARTHELEMY, MD Hôpitaux du Léman Recruiting Thonon-les-bains, France, 74200 Contact: Francesco DEL PIANO Principal Investigator: Francesco DEL PIANO CHI de Toulon - Hôpital Sainte-Musse Recruiting Toulon, France Contact: Xavier TCHIKNAVORIAN, MD Principal Investigator: Xavier TCHIKNAVORIAN, MD Institut Claudius Regaud Recruiting Toulouse, France Contact: Florence Dalenc, MD Principal Investigator: Florence Dalenc, MD Institut Gustave Roussy Recruiting Villejuif, France Contact: Monica ARNEDOS, MD Principal Investigator: Monica ARNEDOS, MD Collapse << |
NCT02620839 | Solid Tumors | Phase 1 | Recruiting | March 2020 | United States, California ... more >> UCSF Helen Diller Family Comprehensive Cancer Center Recruiting San Francisco, California, United States, 94143-1711 Contact: Pamela N. Munster, MD 877-827-3222 cancertrials@ucsf.edu Collapse << |
靶点 | Description | IC50 |
---|---|---|
PI3Kα | IC50:5nM |
联系我们
官方电话:400-920-2911
二维码
微信公众号 CSN官网